About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
miRNAs in MM: Dysregulated miRNA Expression Cancer Cells, miR-221/222 Cluster in More Favorable Prognosis, miR-15a & miR-16 in Bone Disease
By
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
FEATURING
Aristea-Maria Papanota
By
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
FEATURING
Aristea-Maria Papanota
9 views
January 12, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Related Content
AUTOPLAY
ON
25:23
Houston Methodist Hospital
Whole-Body MRI: Past, Present, and Future
Feat.
N. Gupta
03:17
Insights from 2023 IMS Annual Meeting
IMS 2023 Insights: "Highlights From the International Myeloma S…
Feat.
J. Richter
23:34
MyCancerHaven
Experts Discuss the Diagnosis and Management of High-Risk Multiple M…
Feat.
R. Vij,
M. Alsina
41:54
University of Colorado Division of Hematology
Overview of Pathophysiology, Diagnosis and Management of Multiple My…
Feat.
K. Sidor
10:23
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "iStopMM Study - Revised Definition of Free …
Feat.
T. Einarsson Long
26:24
Dana-Farber Cancer Institute
Myeloma 101: Diagnosis, Prognosis & Risk
Feat.
N. Munshi
15:21
MyCancerHaven
Response Assessment and Utility of MRD in Multiple Myeloma
Feat.
R. Vij,
A. Rossi
42:37
University of Colorado Department of Medicine
Multiple Myeloma in 2023: An Oncological Success Story
Feat.
P. Forsberg
04:34
Icahn School of Medicine at Mount Sinai
Revisiting the Role of Alkylating Agents in Myeloma: Up-to-Date Evid…
Feat.
J. Richter
10:13
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: MM
Feat.
K. Patel
10:32
Penn Medicine Abramson Cancer Center
Penn Medicine Updates From Recent Meetings in Hematologic Malignanci…
Feat.
A. Garfall
47:04
Dana-Farber Cancer Institute
Future Directions for Novel & Next Gen Therapy in the Management…
Feat.
P. Richardson
47:07
Louisville Hematology Highlights
Updates on the Progress in Multiple Myeloma
Feat.
D. Reece
26:08
GRACE
2023 Updates on Advances in Multiple Myeloma
Feat.
S. Kumar
10:25
5th SOHO Italy Annual Conference
SOHO Italy 2023: Is It Time for a Biomarkers-Driven Approach in Smol…
Feat.
I. Ghobrial
10:00
i3 Health
Expert Guidance on Current Standards and New Directions in Newly Dia…
Feat.
U. Shah
45:43
MedNews Week
Multiple Myeloma in 2022: Developments, Directions, and Disparities
Feat.
J. Mikhael
20:28
Dana-Farber Cancer Institute
The PROMISE of Early Detection and Interception in Myeloma
Feat.
I. Ghobrial
15:28
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Next Generation Therapeutics (Degraders & Targeted Th…
Feat.
A. Nooka
19:18
Total Health
Updates to Management of Patients With Multiple Myeloma
Feat.
S. Kumar
